- Home
- AOMR vs MNPR Comparison
AOMR vs MNPR Comparison
Compare AOMR & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- MNPR
- Stock Information
- Founded
- AOMR 2018
- MNPR 2014
- Country
- AOMR United States
- MNPR United States
- Employees
- AOMR N/A
- MNPR N/A
- Industry
- AOMR Real Estate Investment Trusts
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- AOMR Real Estate
- MNPR Health Care
- Exchange
- AOMR Nasdaq
- MNPR Nasdaq
- Market Cap
- AOMR 237.8M
- MNPR 249.5M
- IPO Year
- AOMR 2021
- MNPR 2019
- Fundamental
- Price
- AOMR $9.11
- MNPR $31.73
- Analyst Decision
- AOMR Strong Buy
- MNPR Strong Buy
- Analyst Count
- AOMR 6
- MNPR 5
- Target Price
- AOMR $11.75
- MNPR $59.50
- AVG Volume (30 Days)
- AOMR 170.3K
- MNPR 18.2K
- Earning Date
- AOMR 05-05-2025
- MNPR 05-13-2025
- Dividend Yield
- AOMR 14.05%
- MNPR N/A
- EPS Growth
- AOMR N/A
- MNPR N/A
- EPS
- AOMR 1.51
- MNPR N/A
- Revenue
- AOMR $57,147,000.00
- MNPR N/A
- Revenue This Year
- AOMR N/A
- MNPR N/A
- Revenue Next Year
- AOMR $7.33
- MNPR N/A
- P/E Ratio
- AOMR $6.03
- MNPR N/A
- Revenue Growth
- AOMR N/A
- MNPR N/A
- 52 Week Low
- AOMR $7.36
- MNPR $1.72
- 52 Week High
- AOMR $13.32
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- AOMR 42.15
- MNPR 37.28
- Support Level
- AOMR $9.06
- MNPR $34.02
- Resistance Level
- AOMR $9.39
- MNPR $36.82
- Average True Range (ATR)
- AOMR 0.24
- MNPR 3.54
- MACD
- AOMR -0.13
- MNPR -0.71
- Stochastic Oscillator
- AOMR 7.73
- MNPR 27.91
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.